TY - JOUR
T1 - Management of status epilepticus
T2 - a narrative review
AU - Migdady, I.
AU - Rosenthal, E. S.
AU - Cock, H. R.
N1 - Funding Information:
ER serves on the advisory board for UCB Pharma, Inc. and Ceribell, Inc., has institutional contracts between Masachusetts General Hospital (MGH) and Sage Therapeutics and between MGH and Marinus Pharmaceuticals and received grants from the US National Institutes of Health HC reports non‐financial support from the International League Against Epilepsy, Novartis, GWPharma and received grants from US National Institutes of Health Institute of Neurological Disorders and Stroke. No other competing interests declared.
Publisher Copyright:
© 2022 Association of Anaesthetists
PY - 2022/1
Y1 - 2022/1
N2 - Status epilepticus causes prolonged or repetitive seizures that, if left untreated, can lead to neuronal injury, severe disability, coma and death in paediatric and adult populations. While convulsive status epilepticus can be diagnosed using clinical features alone, non-convulsive status epilepticus requires confirmation by electroencephalogram. Early seizure control remains key in preventing the complications of status epilepticus. This is especially true for convulsive status epilepticus, which has stronger evidence supporting the benefit of treatment on outcomes. When status epilepticus becomes refractory, often due to gamma-aminobutyric acid and N-methyl-D-aspartate receptor modulation, anaesthetic drugs are needed to suppress seizure activity, of which there is limited evidence regarding the selection, dose or duration of their use. Seizure monitoring with electroencephalogram is often needed when patients do not return to baseline or during anaesthetic wean; however, it is resource-intensive, costly, only available in highly specialised centres and has not been shown to improve functional outcomes. Thus, the treatment goals and aggressiveness of therapy remain under debate, especially for non-convulsive status epilepticus, where prolonged therapeutic coma can lead to severe complications. This review presents an evidence-based, clinically-oriented and comprehensive review of status epilepticus and its definitions, aetiologies, treatments, outcomes and prognosis at different stages of the patient’s journey.
AB - Status epilepticus causes prolonged or repetitive seizures that, if left untreated, can lead to neuronal injury, severe disability, coma and death in paediatric and adult populations. While convulsive status epilepticus can be diagnosed using clinical features alone, non-convulsive status epilepticus requires confirmation by electroencephalogram. Early seizure control remains key in preventing the complications of status epilepticus. This is especially true for convulsive status epilepticus, which has stronger evidence supporting the benefit of treatment on outcomes. When status epilepticus becomes refractory, often due to gamma-aminobutyric acid and N-methyl-D-aspartate receptor modulation, anaesthetic drugs are needed to suppress seizure activity, of which there is limited evidence regarding the selection, dose or duration of their use. Seizure monitoring with electroencephalogram is often needed when patients do not return to baseline or during anaesthetic wean; however, it is resource-intensive, costly, only available in highly specialised centres and has not been shown to improve functional outcomes. Thus, the treatment goals and aggressiveness of therapy remain under debate, especially for non-convulsive status epilepticus, where prolonged therapeutic coma can lead to severe complications. This review presents an evidence-based, clinically-oriented and comprehensive review of status epilepticus and its definitions, aetiologies, treatments, outcomes and prognosis at different stages of the patient’s journey.
UR - http://www.scopus.com/inward/record.url?scp=85122705657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122705657&partnerID=8YFLogxK
U2 - 10.1111/anae.15606
DO - 10.1111/anae.15606
M3 - Review article
C2 - 35001380
AN - SCOPUS:85122705657
SN - 0003-2409
VL - 77
SP - 78
EP - 91
JO - Anaesthesia
JF - Anaesthesia
IS - S1
ER -